Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-221 in Chronic Spontaneous Urticaria
NCT05298215Phase 2Unknown
- Sponsor
- United BioPharma
- Start
- Oct 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ub-221 in chronic spontaneous urticaria (CSU) (3 arms), sponsored by United BioPharma. Primary endpoint: Change in serum free IgE level from baseline at Day 83. Status: unknown.
02
Drugs
ub-221
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT05298215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298215.